Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

Shimabukuro, T. T., Nguyen, M., Martin, D., & Destefano, F. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 627

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020

Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536

Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Rüggeberg, J. U., Gold, M., Bayas, J. M., Blum, M. D., Bonhoeffer, J., Friedlander, S. F., Brito, G. D. S., Heininger, U., Imoukhuede, E. B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383

Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020

Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P., & Anderson, R. N. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6942e2 · Cited by 373

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Shimabukuro, T. T., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.0600 · Cited by 327

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020

Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm695152e1 · Cited by 317

Vaccine-associated hypersensitivity

McNeil, M. M., & Destefano, F. R. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.971 · Cited by 274

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021

CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 270

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,146

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

McMahon, D. E., Amerson, E. H., Rosenbach, M. A., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., THIERS, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Klein, N. P., Lewis, N., Goddard, K., FIREMAN, B. H., Zerbo, O., Hanson, K. E., Donahue, J. G., Kharbanda, E. O., Naleway, A. L., Nelson, J. C., et al. (2021) · JAMA · doi:10.1001/jama.2021.15072 · Cited by 633

Unlocking the promise of mRNA therapeutics

Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612

To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives

Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535

The landscape of mRNA nanomedicine

Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511

The dawn of mRNA vaccines: the COVID-19 case

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504

Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products

Ibrahim, M. Y., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., El-Garhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 481

A Comprehensive Review of mRNA Vaccines

Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

Gee, J., Marquez, P., Su, J., Calvert, G. M., Liu, R., Myers, T., Nair, N., Martin, S., Clark, T., Markowitz, L., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7008e3 · Cited by 395

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Borobia, A. M., Carcas, A. J., Pérez‐Olmeda, M., Castaño, L. A., Bertran, M. J., García‐Pérez, J., Campins, M., Portolés, A., González-Pérez, M., Morales, M. T. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01420-3 · Cited by 348

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs

Suzuki, Y., & Ishihara, H. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100424 · Cited by 323

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Blumenthal, K. G., Robinson, L. B., Camargo, C. A., Shenoy, E. S., Banerji, A., Landman, A., & Wickner, P. G. (2021) · JAMA · doi:10.1001/jama.2021.3976 · Cited by 274

mRNA Vaccines in the COVID-19 Pandemic and Beyond

Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 260

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D. A., & Yu, H. (2021) · BMC Medicine · doi:10.1186/s12916-021-02059-5 · Cited by 245

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

Català, A., Muñoz‐Santos, C., Galván‐Casas, C., Riesco, M. R., Revilla‐Nebreda, D., Truyols, A. S., Giavedoni, P., Llamas‐Velasco, M., González‐Cruz, C., Cubiró, X., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20639 · Cited by 237

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Greenhawt, M., Abrams, E. M., Shaker, M. S., Chu, D. K., Khan, D. A., Akin, C., Alqurashi, W., Arkwright, P. D., Baldwin, J. L., Ben‐Shoshan, M., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.006 · Cited by 206

ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine

Shakoor, M. T., Birkenbach, M. P., & Lynch, M. R. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.016 · Cited by 189

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

Rosenblum, H. G., Gee, J. M., Liu, R., Marquez, P., Zhang, B., Strid, P., Abara, W. E., McNeil, M. M., Myers, T. R., Hause, A. M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00054-8 · Cited by 180

Recent Advancement in mRNA Vaccine Development and Applications

Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187

Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region

Muhaidat, N., Alshrouf, M. A., Azzam, M., Karam, A. M., Al-Nazer, M., & Al-Ani, A. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s352167 · Cited by 168

Targeted modulation of immune cells and tissues using engineered biomaterials

Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 170

COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): Similarities and differences

Scholkmann, F., & May, C.-A. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154497 · Cited by 177

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

Wolfson, A. R., Robinson, L. B., Li, L., McMahon, A. E., Cogan, A. S., Fu, X., Wickner, P. G., Samarakoon, U., Saff, R. R., Blumenthal, K. G., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.010 · Cited by 140

Lack of consideration of sex and gender in COVID-19 clinical studies

Brady, E., Nielsen, M. W., Andersen, J. P., & Oertelt‐Prigione, S. (2021) · Nature Communications · doi:10.1038/s41467-021-24265-8 · Cited by 147

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

Luxi, N., Giovanazzi, A., Capuano, A., Crisafulli, S., Cutroneo, P. M., Fantini, M. P., Ferrajolo, C., Moretti, U., Poluzzi, E., Raschi, E., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01131-6 · Cited by 142

Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System

Warren, C. M., Snow, T. T., Lee, A., Shah, M. M., Heider, A., Blomkalns, A. L., Betts, B. A., Buzzanco, A. S., González, J. C., Chinthrajah, R. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25524 · Cited by 135

Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity

Hartwell, B. L., Melo, M. B., Xiao, P., Lemnios, A. A., Li, N., Chang, J. Y. H., Yu, J., Gebre, M. S., Chang, A., Maiorino, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1413 · Cited by 112

Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis

Maranini, B., Bortoluzzi, A., Silvagni, E., & Govoni, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030499 · Cited by 111

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape

Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 114

Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine

Green, M. S., Peer, V., Magid, A., HaGani, N., Anis, E., & Nitzan, D. (2022) · Vaccines · doi:10.3390/vaccines10020233 · Cited by 109

Current Developments and Challenges of mRNA Vaccines

Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111

COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group

Kim, M., Lee, Y. W., Kim, S. R., Kim, J., Min, T. K., Park, H., Shin, M., Ye, Y., Lee, S., Lee, J., et al. (2021) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2021.13.4.526 · Cited by 94

COVID-19 vaccines: Considering sex differences in efficacy and safety

Jensen, A., Strømme, M., Moyassari, S., Chadha, A. S., Tartaglia, M. C., Szoeke, C. E. I., & Ferretti, M. T. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106700 · Cited by 94

Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis

Mateja, A., Wang, Q., Chovanec, J., Kim, J., Wilson, K. J., Schwartz, L. B., Glover, S. C., Carter, M. C., Metcalfe, D. D., Brittain, E., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.007 · Cited by 91

The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines

Bigini, P., Gobbi, M., Bonati, M. R., Clavenna, A., Zucchetti, M., Garattini, S. K., & Pasut, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-01001-3 · Cited by 86

Ocular adverse events following vaccination: overview and update

Cheng, J. Y., & Margo, C. E. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.04.001 · Cited by 79

Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines

Robinson, L. B., Fu, X., Hashimoto, D. M., Wickner, P. G., Shenoy, E. S., Landman, A., & Blumenthal, K. G. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2114 · Cited by 79

COVID-19 mRNA Vaccine and Myocarditis

Singh, B., Kaur, P., Cedeno, L., Brahimi, T., Patel, P., Virk, H., Shamoon, F. E., & Bikkina, M. (2021) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2021_002681 · Cited by 78

Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain

Vassallo, A. J., Shajahan, S., Harris, K., Hallam, L., Hockham, C., Womersley, K., Woodward, M., & Sheel, M. (2021) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2021.761511 · Cited by 78

The impact of information sources on COVID-19 vaccine hesitancy and resistance in sub-Saharan Africa

Osuagwu, U. L., Mashige, K. P., Ovenseri-Ogbomo, G. O., Envuladu, E. A., Abu, E. K., Miner, C. A., Timothy, C. G., Ekpenyong, B. N., Langsi, R., Amiebenomo, O. M.-A., et al. (2023) · BMC Public Health · doi:10.1186/s12889-022-14972-2 · Cited by 74

mRNA vaccines: The future of prevention of viral infections?

Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 75

Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-01505-x · Cited by 68

COVID ‐19: vaccination problems

Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 69

Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines

McMurry, R., Lenehan, P. J., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A., Anand, P., Agarwal, V., O’Horo, J. C., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.006 · Cited by 65

Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don't give up on the second dose!

Krantz, M. S., Bruusgaard‐Mouritsen, M. A., Koo, G., Phillips, E. J., Stone, C. A., & Garvey, L. H. (2021) · Allergy · doi:10.1111/all.14958 · Cited by 65

Brief review of the mRNA vaccines COVID-19

Vitiello, A., & Ferrara, F. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00811-0 · Cited by 64

Anaphylaxis: Revision of the Brighton collaboration case definition

Gold, M., Amarasinghe, A., Greenhawt, M., Kelso, J. M., Kochhar, S., Thong, B. Y., Top, K. A., Turner, P., Worm, M., & LAW, B. J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.027 · Cited by 61

COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals

Chavda, V. P., Vora, L. K., & Vihol, D. R. (2021) · Clinical Complementary Medicine and Pharmacology · doi:10.1016/j.ccmp.2021.100004 · Cited by 60

Tailoring the physicochemical properties of nanomaterials for immunomodulation

Deng, J., Wang, J., Shi, J., Li, H., Lu, M., Fan, Z., Gu, Z., & Cheng, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114039 · Cited by 62

Nanoparticle Surface Engineering with Heparosan Polysaccharide Reduces Serum Protein Adsorption and Enhances Cellular Uptake

Yang, W., Wang, L., Fang, M., Sheth, V. M., Zhang, Y., Holden, A., Donahue, N. D., Green, D. E., Frickenstein, A. N., Mettenbrink, E. M., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00349 · Cited by 59

Messenger RNA vaccines for cancer immunotherapy: progress promotes promise

Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60

Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery

Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 59

Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives

Gaballa, S. A., Shimizu, T., Ando, H., Takata, H., Emam, S. E., Ramadan, E., Naguib, Y. W., Mady, F. M., Khaled, K. A., & Ishida, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.001 · Cited by 60

Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study

Hatziantoniou, S., Maltezou, H. C., Tsakris, A., Poland, G. A., & Anastassopoulou, C. G. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.073 · Cited by 53

Vaccine hesitancy: the greatest threat to COVID-19 vaccination programs

Nossier, S. A. (2021) · Journal of the Egyptian Public Health Association · doi:10.1186/s42506-021-00081-2 · Cited by 55

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

Seirafianpour, F., Pourriyahi, H., Mesgarha, M. G., Mohammad, A. P., Shaka, Z., & Goodarzi, A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15461 · Cited by 50

Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions

Pitlick, M. M., Sitek, A. N., Kinate, S., Joshi, A. Y., & Park, M. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.012 · Cited by 48

Vaccine allergy: evidence to consider for COVID-19 vaccines

Nilsson, L. E., Csuth, Á., Storsæter, J., Garvey, L. H., & Jenmalm, M. C. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000762 · Cited by 48

Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021

Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48

Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals

Nittner‐Marszalska, M., Rosiek‐Biegus, M., Kopeć, A., Pawłowicz, R., Kosińska, M., Łata, A., & Szenborn, L. (2021) · Vaccines · doi:10.3390/vaccines9060553 · Cited by 49

Parents’ hesitation about getting their children vaccinated against COVID-19 in Japan

Yoda, T., & Katsuyama, H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1981087 · Cited by 48

COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation

Mirza, S. A., Sheikh, A. A. E., Barbera, M., Ijaz, Z., Javaid, M. A., Shekhar, R., Pal, S., & Sheikh, A. B. (2022) · Infectious Disease Reports · doi:10.3390/idr14020023 · Cited by 50

Vaccination Against COVID-19: A Longitudinal Trans-Theoretical Study to Determine Factors that Predict Intentions and Behavior

Shiloh, S., Peleg, S., & Nudelman, G. (2021) · Annals of Behavioral Medicine · doi:10.1093/abm/kaab101 · Cited by 49

COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach

Banerji, A., Wolfson, A. R., Wickner, P. G., Cogan, A. S., McMahon, A. E., Saff, R. R., Robinson, L. B., Phillips, E. J., & Blumenthal, K. G. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.053 · Cited by 47

Immunity to SARS-CoV-2: Lessons Learned

FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46

Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis

Brockow, K., Mathes, S., Fischer, J., Volc, S., Darsow, U. G., Eberlein, B., & Biedermann, T. (2021) · Allergy · doi:10.1111/all.15183 · Cited by 46

Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study

Wong, C. K. H., Lau, K. T. K., Xiong, X., Au, I. C. H., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Li, X., Chan, E. W., Gao, L., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004018 · Cited by 45

Cutaneous manifestations of COVID ‐19 and COVID ‐19 vaccination

Nakashima, C., Kato, M., & Otsuka, A. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16651 · Cited by 48

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

Bonadonna, P., Brockow, K., Niedoszytko, M., Elberink, H. O., Akin, C., Nedoszytko, B., Butterfield, J. H., Álvarez‐Twöse, I., Sotlar, K., Schwaab, J., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.041 · Cited by 42

Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond

Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 44

The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases

Deyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42

Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children

Hutton, D. W., Prosser, L. A., Rose, A. M., Mercon, K. R., Ortega‐Sanchez, I. R., Leidner, A. J., McMorrow, M., Fleming-Dutra, K. E., Prill, M. M., Pike, J. J., et al. (2024) · PEDIATRICS · doi:10.1542/peds.2024-066461 · Cited by 43

Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management

Luxi, N., Giovanazzi, A., Arcolacı, A., Bonadonna, P., Crivellaro, M., Cutroneo, P. M., Ferrajolo, C., Furci, F., Guidolin, L., Moretti, U., et al. (2022) · BioDrugs · doi:10.1007/s40259-022-00536-8 · Cited by 37

Sex differences in airway disease: estrogen and airway surface liquid dynamics

Harvey, B. J., & McElvaney, N. G. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00633-z · Cited by 39

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review

Hodel, K. V. S., Fiuza, B. S. D., Conceição, R. S., Aleluia, A. C. M., Pitanga, T. N., Fonseca, L. M. D. S., Valente, C. O., Rezende, C. S. M. E., & Machado, B. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17060807 · Cited by 38

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.

SeyedAlinaghi, S., Karimi, A., Pashaei, Z., Afzalian, A., Mirzapour, P., Ghorbanzadeh, K., Ghasemzadeh, A., Dashti, M., Nazarian, N., Vahedi, F., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1597 · Cited by 33

Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration

Desai, A. P., Desai, A. P., & Loomis, G. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.058 · Cited by 34

Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report

Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021) · Drug Safety · doi:10.1007/s40264-021-01104-9 · Cited by 33

ISIDOG Consensus Guidelines on COVID-19 Vaccination for Women before, during and after Pregnancy

Donders, G. G. G., Grincevičienė, Š., Haldre, K., Hoffmann, R., Donders, F., Tsiakalos, A., Adriaanse, A. H., de Oliveira, J. M., Ault, K. A., Mendling, W., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132902 · Cited by 35

Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination

Li, L., Robinson, L. B., Patel, R. K., Landman, A., Fu, X., Shenoy, E. S., Hashimoto, D. M., Banerji, A., Wickner, P. G., Samarakoon, U., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.31034 · Cited by 35

Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level

Chouchana, L., Blet, A., Al-Khalaf, M. H., Kafil, T. S., Nair, G. M., Robblee, J. A., Drici, M., Valnet‐Rabier, M., Micallef, J., Salvo, F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2499 · Cited by 33

Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines

Somiya, M., Mine, S., Yasukawa, K., & Ikeda, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.066 · Cited by 32

The short term safety of COVID ‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021

Deng, L., Glover, C., Dymock, M., Pillsbury, A., Marsh, J., Quinn, H., Leeb, A., Cashman, P. M., Snelling, T., Wood, N., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51619 · Cited by 33

mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation

Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 36

Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel

Weber, D. J., Al‐Tawfiq, J. A., Babcock, H. M., Bryant, K. A., Drees, M. L., Elshaboury, R. H., Essick, K., Fakih, M. G., Henderson, D. K., Javaid, W., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.322 · Cited by 33

The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis

Sobczak, M., & Pawliczak, R. (2022) · Clinical and Molecular Allergy · doi:10.1186/s12948-022-00167-y · Cited by 31

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

Zhou, Z., Cortese, M. M., Fang, J., Wood, R. A., Hummell, D. S., Risma, K., Norton, A. E., KuKuruga, M. A., Kirshner, S., Rabin, R. L., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.029 · Cited by 31

Cutaneous adverse events related to COVID ‐19 vaccines: A cross‐sectional questionnaire‐based study of 867 patients

Pourani, M. R., Shahidi‐Dadras, M., Salari, M., Diab, R., Namazi, N., & Abdollahimajd, F. (2021) · Dermatologic Therapy · doi:10.1111/dth.15223 · Cited by 30

Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study

Lee, D. S., Kim, J. W., Lee, K. L., Jung, Y. J., & Kang, H. W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.007 · Cited by 30

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)

Baghban, R., Ghasemian, A., & Mahmoodi, S. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03480-5 · Cited by 35

Vacunas frente a SARS-CoV-2 y piel

Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.05.011 · Cited by 29

Best Practices for COVID-19 Mass Vaccination Clinics

Shakory, S., Eissa, A., Kiran, T., & Pinto, A. D. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2773 · Cited by 29

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Wollina, U., Chiriac, A. E., Kocić, H., Koch, A., & Brzeziński, P. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00876-0 · Cited by 28

Early Impact of Ontario’s COVID-19 Vaccine Rollout on Long-Term Care Home Residents and Health Care Workers

Brown, K. A., Stall, N. M., Vanniyasingam, T., Buchan, S. A., Daneman, N., Hillmer, M. P., Hopkins, J. P., Johnstone, J., Maltsev, A., McGeer, A., et al. (2021) · doi:10.47326/ocsat.2021.02.13.1.0 · Cited by 28

The conundrum of COVID-19 mRNA vaccine–induced anaphylaxis

Khalid, M. B., & Frischmeyer‐Guerrerio, P. A. (2022) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2022.10.003 · Cited by 27

mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation

Jaggers, J. L., & Wolfson, A. R. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01065-2 · Cited by 29

A review of the safety and efficacy of current COVID-19 vaccines

Huang, Z., Su, Y., Zhang, T., & Xia, N. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0893-y · Cited by 28

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance

Nasreen, S., Calzavara, A. J., Buchan, S. A., Thampi, N., Johnson, C., Wilson, S. E., & Kwong, J. C. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.065 · Cited by 26

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Shimabukuro, T. T., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.0600 · Cited by 327

Allergic Reactions to the Pfizer-BioNTech and Moderna COVID-19 Vaccines: Early Reports

Baum, S. G. (2021) · Journal watch · doi:10.1056/nejm-jw.na53087 · Cited by 2

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021

CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 270

Anaphylaxis to vaccinations: A review of the literature and evaluation of the COVID-19 mRNA vaccinations

Kuder, M. M., Lang, D. M., & Patadia, D. D. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.ccc075 · Cited by 10

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020

CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7002e1 · Cited by 481